

[\[Antiviral and antifibrotic therapies reduce occurrence of ...](#)

<https://pubmed.ncbi.nlm.nih.gov/31270040>

Objective: To compare the efficacy and safety of different antiviral and antifibrotic regimens in patients with chronic hepatitis B (CHB) and hepatic fibrosis and the incidence of hepatocellular carcinoma (HCC) associated with these therapies. Methods: A total of 840 patients with CHB and concurrent hepatic fibrosis, who received antiviral therapy in Nanfang Hospital between June, 2010 and ...

[A Review Of Current And Upcoming Treatment Modalities In ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6863115>

Nov 15, 2019 - Primary endpoint is to confirm the efficacy and safety of treatment of fibrosis. Thyroid receptor β agonist: VK-2809: Loomba et al.136-Primary endpoint was reduction in LDL-C.-Reductions in liver fat on imaging-Studies assessing histologic improvement needed-Longer term studies assessing safety and efficacy needed: MGL-3196: Harrison et al.144

Cited by: 5 Author: Suroosree Ganguli, Peter DeLeeuw, Sanja...

Published Year: 2019

Search Tools

Turn off Hover Translation (关闭取词)

国内版 国际版

Efficacy and Safety of Anti-Hepatic Fibrosis Drugs



ALL IMAGES VIDEOS

3,590,000 Results Any time ▾

[\[Antiviral and antifibrotic therapies reduce occurrence of ...
https://pubmed.ncbi.nlm.nih.gov/31270040](https://pubmed.ncbi.nlm.nih.gov/31270040)

Objective: To compare the **efficacy and safety** of different antiviral and antifibrotic regimens in patients with chronic hepatitis B (CHB) and hepatic **fibrosis** and the incidence of hepatocellular carcinoma (HCC) associated with these therapies. Methods: A total of 840 patients with CHB and concurrent hepatic **fibrosis**, who received antiviral therapy in Nanfang Hospital between June, 2010 and ...

Author: Yuchen Zhou, Chengguang Hu, Guos... **Publish Year:** 2019

[Disease modifying anti-rheumatic drugs in people with ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481469](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481469)

Jul 10, 2012 · This systematic review has identified the need for a well-designed adequately powered randomised controlled trial to assess the **efficacy and safety** of disease-modifying anti-rheumatic **drugs** for the management of cystic **fibrosis**-related arthropathy and hypertrophic osteoarthropathy in adults and children with cystic **fibrosis**.

Cited by: 6 **Author:** Judith Thornton, Satyapal Rangaraj
Publish Year: 2012

2 Name of Journal: *World Journal of Gastroenterology*
Manuscript NO: 58599
Manuscript Type: REVIEW

Efficacy and Safety of Anti-Hepatic Fibrosis Drugs

Konstantinos Damiris, Zaid H Tafesh, Nikolaos Pyrsopoulos

Match Overview

Match #	Source	Words	Similarity
1	Crossref	76 words	1%
	Joseph J. Atukal, Paul J. Thuluvath. "Reversal of NASH fi... osis with pharmacotherapy", <i>Hepatology International</i> , 201		
2	Internet	70 words	1%
	crawled on 30-Aug-2019 f6publishing.blob.core.windows.net		
3	Internet	42 words	1%
	crawled on 25-May-2020 www.dovepress.com		
4	Internet	29 words	<1%
	crawled on 15-Jul-2020 link.springer.com		
5	Internet	28 words	<1%
	crawled on 20-Feb-2019 issuu.com		
6	Internet	27 words	<1%
	crawled on 27-Mar-2019		

国内版 国际版

Efficacy and safety of anti-hepatic fibrosis drugs



ALL IMAGES VIDEOS

3,410,000 Results Any time ▾

[Antiviral and antifibrotic therapies reduce occurrence of ...

<https://pubmed.ncbi.nlm.nih.gov/31270040>

Objective: To compare the **efficacy and safety** of different antiviral and antifibrotic regimens in patients with chronic hepatitis B (CHB) and hepatic **fibrosis** and the incidence of hepatocellular carcinoma (HCC) associated with these therapies. Methods: A total of 840 patients with CHB and concurrent hepatic **fibrosis**, who received antiviral therapy in Nanfang Hospital between June, ...

Author: Yuchen Zhou, Chengguang Hu, Guo... **Publish Year:** 2019

Advances in Anti Hepatic Fibrotic Therapy With Traditional ...

<https://pubmed.ncbi.nlm.nih.gov/31891799>

According to the principle of syndrome differentiation and treatment, Liver **fibrosis** patients with different syndromes are treated with different herbal formula, which increases the difficulty of clinical **efficacy** research. YCHD and XYXD research ...

Cited by: 2 **Author:** Hui Li

Publish Year: 2020

Safety and efficacy of bridging to lung transplantation ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5116160>

Nov 18, 2016 · **Safety and efficacy of antifibrotic drugs** in IPF patients undergoing LTx were investigated in a single-centre retrospective cohort analysis. Results A total of nine patients, receiving **antifibrotic therapy** for 419 ± 315 days until subsequent LTx, were included.

Cited by: 56 **Author:** Isabelle Delanote, Wim A. Wuyts, Jonas...

Publish Year: 2016

Novel targeted therapies for the management of liver fibrosis

<https://www.tandfonline.com/doi/figure/10.1080/14728214.2020.1735350>

The **efficacy and safety** of these agents will need to be corroborated by larger clinical trials, some of which are ongoing with results expected in the upcoming years. Combination therapy with agents targeting different pathways of fibrogenesis will also be of great interest for the future and will need